Is Palantir Stock a Millionaire Maker?
Palantir (NASDAQ:PLTR) has shot upward over the last year and…
Sell
37
CRL Quote, Financials, Valuation and Earnings
Last price:
$116.82
Seasonality move
:
5.51%
Day range:
$114.24 - $120.14
52-week range:
$91.86 - $254.15
Dividend yield:
0%
P/E ratio:
779.27x
P/S ratio:
1.49x
P/B ratio:
1.73x
Volume:
990K
Avg. volume:
2.1M
1-year change:
-49.77%
Market cap:
$6B
Revenue:
$4B
EPS (TTM):
$0.15
Analysts' Opinion
-
Consensus RatingCharles River Laboratories International has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 16 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $155.28, Charles River Laboratories International has an estimated upside of 32.84% from its current price of $116.89.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $70.00 representing 100% downside risk from its current price of $116.89.
Fair Value
-
According to the consensus of 19 analysts, Charles River Laboratories International has 32.84% upside to fair value with a price target of $155.28 per share.
CRL vs. S&P 500
-
Over the past 5 trading days, Charles River Laboratories International has underperformed the S&P 500 by -0.45% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Charles River Laboratories International does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Charles River Laboratories International revenues have been falling on a year-over-year basis for 5 quarters in a row. In the most recent quarter Charles River Laboratories International reported revenues of $1B.
Earnings Growth
-
Charles River Laboratories International earnings have been falling on a year-over-year basis for 6 quarters in a row. In the most recent quarter Charles River Laboratories International reported earnings per share of -$4.22.
Enterprise value:
8.1B
EV / Invested capital:
--
Price / LTM sales:
1.49x
EV / EBIT:
36.78x
EV / Revenue:
1.99x
PEG ratio (5yr expected):
--
EV / Free cash flow:
16.09x
Price / Operating cash flow:
12.04x
Enterprise value / EBITDA:
13.89x
Gross Profit (TTM):
$1.3B
Return On Assets:
0.28%
Net Income Margin (TTM):
0.55%
Return On Equity:
0.6%
Return On Invested Capital:
0.36%
Operating Margin:
4.72%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $4B | $4.1B | $4B | $1B | $1B | |
| Gross Profit | $1.5B | $1.5B | $1.3B | $364.1M | $284.2M | |
| Operating Income | $651M | $617.3M | $442.3M | $132.9M | $47.3M | |
| EBITDA | $986.1M | $1B | $581.1M | $322.8M | -$86.5M | |
| Diluted EPS | $9.47 | $9.23 | $0.15 | $3.64 | -$4.22 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.2B | $1.3B | $1.4B | $1.6B | $1.4B | |
| Total Assets | $5.5B | $7B | $7.6B | $8.2B | $7.5B | |
| Current Liabilities | $839.8M | $1B | $1.1B | $1.1B | $994.1M | |
| Total Liabilities | $3.3B | $4.4B | $4.6B | $4.5B | $4B | |
| Total Equity | $2.1B | $2.6B | $3B | $3.7B | $3.5B | |
| Total Debt | $1.9B | $2.7B | $2.7B | $2.6B | $2.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $619.6M | $683.9M | $734.6M | $220.9M | $159.4M | |
| Cash From Investing | -$607.9M | -$563.2M | -$245.1M | -$238.4M | -$76.1M | |
| Cash From Financing | -$42.4M | -$85.5M | -$550.9M | $123.6M | -$75.9M | |
| Free Cash Flow | $294.9M | $365.4M | $501.6M | $142.6M | $83.7M | |
CRL
Sector
Market Cap
$6B
$35.2M
Price % of 52-Week High
45.99%
44.63%
Dividend Yield
0%
0%
Shareholder Yield
1.84%
-0.81%
1-Year Price Total Return
-49.77%
-39.07%
Beta (5-Year)
1.500
0.662
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$114.27
200-day SMA
Sell
Level
$181.71
Bollinger Bands (100)
Sell
Level
134.82 - 187.68
Chaikin Money Flow
Buy
Level
11M
20-day SMA
Buy
Level
$115.70
Relative Strength Index (RSI14)
Sell
Level
42.30
ADX Line
Sell
Level
53.97
Williams %R
Sell
Level
-11.4769
50-day SMA
Sell
Level
$144.88
MACD (12, 26)
Buy
Level
6.87
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-20.7M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.4453)
Sell
CA Score
(Annual)
Level (-0.3719)
Buy
Beneish M-Score
(Annual)
Level (-2.9543)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (10.4275)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Stock Forecast FAQ
In the current month, CRL has received 2 Buy ratings 16 Hold ratings, and 1 Sell ratings. The CRL average analyst price target in the past 3 months is $155.28.
-
Where Will Charles River Laboratories International Stock Be In 1 Year?
According to analysts, the consensus estimate is that Charles River Laboratories International share price will rise to $155.28 per share over the next 12 months.
-
What Do Analysts Say About Charles River Laboratories International?
Analysts are divided on their view about Charles River Laboratories International share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Charles River Laboratories International is a Sell and believe this share price will drop from its current level to $70.00.
-
What Is Charles River Laboratories International's Price Target?
The price target for Charles River Laboratories International over the next 1-year time period is forecast to be $155.28 according to 19 Wall Street analysts, 2 of them rate the stock a Buy, 1 rates the stock a Sell, and 16 analysts rate the stock a Hold.
-
Is CRL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Charles River Laboratories International is a Hold. 16 of 19 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CRL?
You can purchase shares of Charles River Laboratories International via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Charles River Laboratories International shares.
-
What Is The Charles River Laboratories International Share Price Today?
Charles River Laboratories International was last trading at $116.82 per share. This represents the most recent stock quote for Charles River Laboratories International. Yesterday, Charles River Laboratories International closed at $116.89 per share.
-
How To Buy Charles River Laboratories International Stock Online?
In order to purchase Charles River Laboratories International stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is QuantumScape a Buy Now?
QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…
Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
68
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
62
RGC alert for May 2
Regencell Bioscience Holdings [RGC] is down 7.14% over the past day.
Sell
36
WGS alert for May 2
GeneDx Holdings [WGS] is up 5.28% over the past day.
Sell
42
VICR alert for May 2
Vicor [VICR] is up 2.87% over the past day.
